Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?

被引：4

作者：

Al Farsi, Abdulaziz ^{[1
]}

Ellis, Peter M. ^{[1
]}

机构：

[1] Juravinski Canc Ctr, Dept Med Oncol, Hamilton, ON L8V 5C2, Canada

来源：

JOURNAL OF THORACIC DISEASE | 2015年 / 7卷 / 03期

关键词：

PHASE-III TRIAL; DOUBLE-BLIND; GROWTH-FACTOR; PLUS ERLOTINIB; CANCER; PLACEBO; BEVACIZUMAB; CHEMOTHERAPY; CARBOPLATIN; VANDETANIB;

D O I：

10.3978/j.issn.2072-1439.2015.01.41

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：214 / 216

页数：3

共 20 条

[1] Biology of platelet-derived growth factor and its involvement in disease [J].

Alvarez, Ricardo H. ;

Kantarjian, Hagop M. ;

Cortes, Jorge E. .

MAYO CLINIC PROCEEDINGS, 2006, 81 (09) :1241-1257

[2] Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis [J].

Bonnesen, Barbara ;

Pappot, Helle ;

Holmstav, Julie ;

Skov, Birgit Guldhammer .

LUNG CANCER, 2009, 66 (03) :314-318

[3] American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes [J].

Ellis, Lee M. ;

Bernstein, David S. ;

Voest, Emile E. ;

Berlin, Jordan D. ;

Sargent, Daniel ;

Cortazar, Patricia ;

Garrett-Mayer, Elizabeth ;

Herbst, Roy S. ;

Lilenbaum, Rogerio C. ;

Sima, Camelia ;

Venook, Alan P. ;

Gonen, Mithat ;

Schilsky, Richard L. ;

Meropol, Neal J. ;

Schnipper, Lowell E. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1277-+

[4] Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions [J].

Ellis, Peter M. ;

Al-Saleh, Khalid .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (01) :47-58

[5] A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer [J].

Ellis, Peter M. ;

Blais, Normand ;

Soulieres, Dennis ;

Ionescu, Diana N. ;

Kashyap, Meenakshi ;

Liu, Geoff ;

Melosky, Barb ;

Reiman, Tony ;

Romeo, Phillippe ;

Shepherd, Frances A. ;

Tsao, Ming-Sound ;

Leighl, Natasha B. .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (08) :1379-1391

[6]

Hanna NH, 2013, J CLIN ONCOL, V31

[7] Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial [J].

Herbst, Roy S. ;

Ansari, Rafat ;

Bustin, Frederique ;

Flynn, Patrick ;

Hart, Lowell ;

Otterson, Gregory A. ;

Vlahovic, Gordana ;

Soh, Chang-Heok ;

O'Connor, Paula ;

Hainsworth, John .

LANCET, 2011, 377 (9780) :1846-1854

[8] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial [J].

Herbst, Roy S. ;

Sun, Yon ;

Eberhardt, Wilfried E. E. ;

Germonpre, Paul ;

Saijo, Nagahiro ;

Zhou, Caicun ;

Wang, Jie ;

Li, Longyun ;

Kabbinavar, Fairooz ;

Ichinose, Yukito ;

Qin, Shukui ;

Zhang, Li ;

Biesma, Bonne ;

Heymach, John V. ;

Langmuir, Peter ;

Kennedy, Sarah J. ;

Tada, Hiroomi ;

Johnson, Bruce E. .

LANCET ONCOLOGY, 2010, 11 (07) :619-626

[9] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[10] BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [J].

Hilberg, Frank ;

Roth, Gerald J. ;

Krssak, Martin ;

Kautschitsch, Susanna ;

Sommergruber, Wolfgang ;

Tontsch-Grunt, Ulrike ;

Garin-Chesa, Pilar ;

Bader, Gerd ;

Zoephel, Andreas ;

Quant, Jens ;

Heckel, Armin ;

Rettig, Wolfgang J. .

CANCER RESEARCH, 2008, 68 (12) :4774-4782

← 1 2 →